SARS-CoV-2 Lambda variant exhibits higher infectivity and immune resistance

 Izumi Kimura, Yusuke Kosugi, Jiaqi Wu, Daichi Yamasoba, Erika P Butlertanaka, Yuri L Tanaka, Yafei Liu, Kotaro Shirakawa, Yasuhiro Kazuma, Ryosuke Nomura, Yoshihito Horisawa,  

View ORCID ProfileKenzo Tokunaga, Akifumi Takaori-Kondo,  View ORCID ProfileHisashi Arase, The Genotype to Phenotype Japan (G2P-Japan) Consortium, Akatsuki Saito,  View ORCID ProfileSo Nakagawa,  View ORCID ProfileKei Sato

doi: https://doi.org/10.1101/2021.07.28.454085

This article is a preprint and has not been certified by peer review [what does this mean?].

PDF:: https://www.biorxiv.org/content/10.1101/2021.07.28.454085v1.full.pdf

Abstract

SARS-CoV-2 Lambda, a new variant of interest, is now spreading in some South American countries; however, its virological features and evolutionary trait remain unknown. Here we reveal that the spike protein of the Lambda variant is more infectious and it is attributed to the T76I and L452Q mutations. The RSYLTPGD246-253N mutation, a unique 7-amino-acid deletion mutation in the N-terminal domain of the Lambda spike protein, is responsible for evasion from neutralizing antibodies. Since the Lambda variant has dominantly spread according to the increasing frequency of the isolates harboring the RSYLTPGD246-253N mutation, our data suggest that the insertion of the RSYLTPGD246-253N mutation is closely associated with the massive infection spread of the Lambda variant in South America.

Competing Interest Statement

The authors have declared no competing interest.

https://www.biorxiv.org/content/10.1101/2021.07.28.454085v1